Showing 1,421 - 1,440 results of 144,150 for search '(( i we decrease ) OR ( 5 ((((step decrease) OR (nn decrease))) OR (a decrease)) ))', query time: 1.78s Refine Results
  1. 1421
  2. 1422
  3. 1423
  4. 1424
  5. 1425
  6. 1426
  7. 1427
  8. 1428
  9. 1429
  10. 1430
  11. 1431
  12. 1432
  13. 1433
  14. 1434

    <b>Dihydroxyacetone decreases the dATP pool, inducing replication stress and genomic instability in BEAS-2B cells</b> by Saddam Hussain (22282372)

    Published 2025
    “…Using a DNA fiber assay we observed decreased replication fork progression, which coincided with increased micronuclei formation. …”
  15. 1435

    Cholesterol Corrects Altered Conformation of MHC-II Protein in <i>Leishmania donovani</i> Infected Macrophages: Implication in Therapy by Koushik Roy (193484)

    Published 2016
    “…<div><p>Background</p><p>Previously we reported that Kala-azar patients show progressive decrease in serum cholesterol as a function of splenic parasite burden. …”
  16. 1436

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  17. 1437

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  18. 1438
  19. 1439
  20. 1440